Clinical Trials Logo

Clinical Trial Summary

In this randomized, double-blind clinical trial including patients with a neurogenic lower urinary tract dysfunction undergoing urodynamic investigation at the Spinal Cord Injury Center, Balgrist University Hospital, Zürich, we aim to investigate whether the detrusor contraction during the ice-water-test is provoked by the ice water or the rapid filling.


Clinical Trial Description

The ice-water-test (IWT) was first described 1957 by Bors and Blinn and it was thought to differentiate between lesions of the upper and lower motoneuron. In cat studies, it was shown that the IWT is a C-fiber mediated lower motoneuron segmental reflex and that these unmyelinated C fibers are associated with cold receptors. This explains the positive IWT in patients with upper motoneuron lesions. In healthy humans, the IWT is positive up to the age of 4 years and becomes negative thereafter since the reflex is centrally inhibited. However, this reflex might be unmasked by a neurological disease and/or injury.

Considering that C-fibers are involved in the pathogenesis of detrusor overactivity, the IWT seems to be a useful diagnostic tool in daily practice. However, although there are many studies published on the IWT, it is unclear whether the detrusor contraction during the IWT is provoked by the ice water or whether it might be caused by the rapid filling. Therefore, we designed this randomized, double-blind trial. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01773213
Study type Interventional
Source Balgrist University Hospital
Contact
Status Completed
Phase N/A
Start date December 2012
Completion date March 2013

See also
  Status Clinical Trial Phase
Recruiting NCT05141487 - Feasibility of Triggered Sacral Neuromodulation for Neurogenic Bladder
Completed NCT01920243 - Evaluation of a Bowel and Bladder Health Management Program for Individuals With Spinal Cord Injury (SCI) N/A
Completed NCT04528784 - Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis N/A
Enrolling by invitation NCT03336424 - Urinary Disorders in Patients With Multiple Sclerosis: Invasive Vs Non-invasive Investigations. N/A
Not yet recruiting NCT05075642 - Multicenter Observational Study for the Evaluation in Clinical Practice of Urinary Disorders in Multiple Sclerosis
Completed NCT02600715 - Reduction of Bladder Injection Pain With Belladonna Opiate Suppository Phase 4
Recruiting NCT04128709 - Measurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use N/A
Not yet recruiting NCT06336304 - NXT Post-Market Clinical Follow-up
Enrolling by invitation NCT05740527 - Ambulatory Closed-loop Stimulation for Bladder Control N/A
Completed NCT02501928 - Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity. Phase 3
Recruiting NCT04819360 - Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis Phase 4
Terminated NCT02044510 - Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients Phase 2/Phase 3
Completed NCT01557244 - A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition Phase 3
Recruiting NCT05380661 - Heart Rate Variability and Anxiety During Urinary Bladder Catheterization N/A
Recruiting NCT04193709 - Recovery of Bladder and Sexual Function After Human Spinal Cord Injury N/A
Completed NCT02582151 - Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder N/A
Active, not recruiting NCT05232253 - Cystoealstometer (Bladder Monitor Device)-Home Use N/A
Completed NCT03405285 - Connected Catheter Clinical Feasibility Study( CFS) N/A
Completed NCT02673047 - Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder N/A
Completed NCT01530620 - Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity Phase 3